Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: Results of a Delphi questionnaire panel from the NETPraxis program

There are clinical situations (CS) in which the use of somatostatin analogs (SSAs) in patients with neuroendocrine tumors (NET) is controversial due to lack of evidence. A Delphi study was conducted to develop common treatment guidelines for these CS, based on clinical practice and expert opinion of Spanish oncologists.